To receive CME credit for this program:
- Read the CME information and mark the checkbox confirming you have read the disclosures to download the PDF file below
- Review the article and illustration
- Login or register at the CME post test website (http://www.bucmetest.com)
- Locate the course code I.ANG11BIOM and take the test
Jointly sponsored by Boston University School of Medicine and the Angiogenesis Foundation
This CME activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through Joint Sponsorship of Boston University School of Medicine and the Angiogenesis Foundation. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Boston University School of Medicine designates this Internet activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Credit will be awarded provided this activity is used and completed according to instructions and a score of 70% or better is achieved. A certificate of credit will be issued to those who successfully complete the examination.
RELEASE AND EXPIRATION
Date of original release: August 30, 2011
Date of expiration: August 29, 2012
Estimated Time To Complete: 1.5 Hours
CME Course Code: I.ANG11BIOM
Practicing oncologists in the U.S., researchers and medical students
Antiangiogenic agents have now been validated for the treatment of multiple cancer types. However, the extent to which individual patients can benefit from these agents is unclear. To optimize the use of these drugs or develop combination regimens that build on their efficacy, it is critical to identify those patients who are most likely to benefit. The goals in cancer research include finding biomarkers that can be used for the early detection of cancer or its recurrence, design individual treatment strategies, and to identify underlying processes involved in the disease. Many biomarkers of angiogenesis and antiangiogenic therapies have been investigated, mainly in retrospective analyses, but none has yet been validated for routine clinical use. It is necessary to conduct randomized, prospective studies to define a suite of predictive, pharmacodynamic and surrogate response biomarkers that identify those patients most likely to benefit from and monitor their response to this novel class of drugs.
The sheer volume of new data emerging on biomarkers poses another major challenge for cancer care providers. Because of the pace at which knowledge on biomarkers is increasing, there is a need to provide an authoritative, accurate, and credible overview of the use of biomarkers in antiangiogenic therapy. A search on PubMed.gov shows 6,926 articles published about biomarkers and angiogenesis, with 754 of them being published in the last 12 months. This publication will provide clinicians who treat and manage cancer patients with a current evidence-based assessment of therapy from the perspective of key opinion leaders who are actively involved in the development of these new therapies.
PROGRAM LEARNING OBJECTIVES
At the completion of this activity, participants should be able to:
- Define and explain biomarkers as they pertain to antiangiogenic therapies.
- Differentiate between prognostic and predictive biomarkers.
- Discuss the underlying rationale for the development of biomarkers for targeted cancer therapies.
- Identify the different types of biomarkers being developed for antiangiogenic cancer therapies and discuss their potential application in real-world clinical practice.
- Discuss data on biomarkers for clinical trials of angiogenesis inhibitors for cancer.
METHOD OF PARTICIPATION
There are no fees for participating in and receiving credit for this online educational activity. The participant should, in order, read the objectives and faculty disclosures, review the educational content, answer the multiple-choice post-test and complete the evaluation. This program is available in PDF format accessible from the Angiogenesis Foundation's website (http://www.angio.org) in the CME section. A print version is also available; for more information contact firstname.lastname@example.org. After reviewing the material, CME credits are available through the Boston University School of Medicine's website (http://www.bucmetest.com) by selecting the name of the program (registration required). Course code: I.ANG11BIOM.
ACKNOWLEDGEMENT OF SUPPORT
This activity is supported by educational grants from Abbott, Bristol-Myers Squibb, Genentech, and Lilly.
Dan G. Duda, D.M.D., Ph.D.
Assistant Professor of Radiation Oncology
Harvard Medical School
Associate Biologist in Radiation Oncology
Edwin L. Steele Laboratory for Tumor Biology
Massachusetts General Hospital
Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relationships with commercial interests. This information is disclosed to CME activity participants. Boston University School of Medicine has procedures to resolve apparent conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.
Dan G. Duda, D.M.D., Ph.D., Harvard Medical School, Massachusetts General Hospital
Dr. Duda has nothing to disclose with regard to commercial interests.
William W. Li, M.D.,
President, the Angiogenesis Foundation, Editor-in-Chief
Dr. Li has nothing to disclose with regard to commercial interests.
Vickie R. Driver, DPM, M.S., FACFAS, Associate Professor of Surgery, Boston University School of Medicine
Dr. Driver receives grant/research support from KCI, sanofi-aventis, 3M, and Baxter. She serves on the Scientific Steering Committee for sanofi-aventis.
Jody Walker, M.S.
BUSM CME Program Manager
BUSM CME Program Manager has nothing to disclose with regard to commercial interests.
Roderick A. Smith, M.S.
Medical Writer, Program Manager, the Angiogenesis Foundation
Medical Writer, Program Manager has nothing to disclose with regard to commercial interests.
DISCUSSION OF UNLABELLED USE
This CME activity contains discussion of published and/or investigational use of: axitinib, bevacizumab (Avastin®), cediranib (Recentin®), cetuximab (Erbitux®), pazopanib, sunitinib (Sutent®), and vandetanib.
The Office of Continuing Medical Education adheres to Boston University’s Conditions of Use and Policy on Computing Ethics. <http://www.bu.edu/cme/policies/privacy_policy.html>
Data gathered from participants who participate in Boston University School of Medicine’s (BUSM) Continuing Medical Education Internet-Based CME program is confidential.
Individual identifiable information is not shared with outside parties. Cumulative data may be analyzed by CME personnel, and, upon occasion, by individuals external to BUSM CME in order to determine trends.
THESE MATERIALS AND ALL OTHER MATERIALS PROVIDED IN CONJUNCTION WITH CONTINUING MEDICAL EDUCATION ACTIVITIES ARE INTENDED SOLEY FOR PURPOSES OF SUPPLEMENTING CONTINUING MEDICAL EDUCATION PROGRAMS FOR QUALIFIED HEALTH CARE PROFESSIONALS. ANYONE USING THE MATERIALS ASSUMES FULL RESPONSIBILITY AND RISK FOR THEIR APPROPRIATE USE. TRUSTEES OF BOSTON UNIVERSITY MAKE NO WARRANTIES OR REPRESENTATIONS WHATSOEVER REGARDING THE ACCURACY, COMPLETENESS, CURRENTNESS, NONINFRINGEMENT, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE OF THE MATERIALS. IN NO EVENT WILL TRUSTEES OF BOSTON UNIVERSITY BE LIABLE TO ANYONE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE MATERIALS. IN NO EVENT SHOULD THE INFORMATION IN THE MATERIALS BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE.
TOPICS AND EDUCATIONAL CONTENT
Mechanisms of action of antiangiogenic therapies for advanced gastric cancer; latest safety and efficacy data on the use of antiangiogenic therapies for gastric cancer; management of side effects; information on ongoing clinical trials. Oncologists are incorporating targeted therapies into standard approved treatment regimens for their patients, and many are enrolling patients into clinical trials using targeted therapies. With dozens of targeted agents in advanced clinical trials for gastric cancer, it is essential that oncologist become aware of these agents, their appropriate use, how they may interact with other treatments, and how to recognize and manage side effects.
This educational program is available in PDF format. To view and print PDF files, you must have Adobe Reader installed on your computer. Most computers already have this software installed. If yours does not, you can download Adobe Reader free from the Adobe Web site: http://www.adobe.com.
If you have questions regarding certificates, please contact BUSM CME by email at email@example.com or visit http://www.bu.edu/cme
For questions about this program, please contact the Angiogenesis Foundation at 617-401-2779 or firstname.lastname@example.org.
Copyright 2011 by the Angiogenesis Foundation. All rights reserved.